跳至主要内容
临床试验/NCT05488470
NCT05488470已完成不适用

Monitoring QT Intervals Using LINQ/LINQII in Patients Undergoing Antiarrhythmic Drug Loading

Medtronic Cardiac Rhythm and Heart Failure3 个研究点 分布在 1 个国家目标入组 22 人开始时间: 2023年2月20日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
22
试验地点
3
主要终点
QT Intervals During Antiarrhythmic Loading Hospitalization

研究概览

简要总结

The LINQ QT Study is a prospective, non-randomized, multi-center, observational, post-market clinical study investigating QT interval changes due to antiarrhythmic drug loading.

详细描述

The purpose of this study is to determine if QT interval changes are detected during and after antiarrhythmic drug loading by the designed QT detection algorithm from LINQ ECG.

The QT intervals during the anti arrhythmic loading hospitalization period will be compared for all patients to analyze QT changes that may be caused due to antiarrhythmic drugs.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients implanted with LINQ/LINQII prior to the study enrollment (no more than 50% patients implanted with LINQII), but no greater than 2.5 years for LINQ or 3.5 years for LINQII, or patients who are indicated to receive a LINQ/LINQII implant at least 7 days prior to antiarrhythmic drug loading
  • Patients who are scheduled to receive antiarrhythmic drug loading
  • Age 18-80
  • Patient is willing and able to comply with the protocol, including follow-up visits, and performing Holter recordings and patient activation transmissions

排除标准

  • Patients who have a contraindication to long-term antiarrhythmic therapy
  • Patients not suitable for long-term antiarrhythmic therapy
  • Patients with a previous, existing cardiac implantation (i.e., cardiac pacemaker or cardiac resynchronization requiring > 40% pacing, implantable cardioverter defibrillator (ICDs))
  • Patients with permanent and persistent AF
  • Co-enrollment in another study or planning to participate in a concurrent device study during the course of this clinical study that could confound the results

结局指标

主要结局

QT Intervals During Antiarrhythmic Loading Hospitalization

时间窗: Assessed in the 2-hr period after each of the first four doses, difference between the maximum and minimum QTc interval reported

The QT intervals during antiarrhythmic loading will be compared for all patients with available LINQ ECG from the baseline anti arrhythmic loading hospitalization to analyze QT changes that may be caused due to antiarrhythmic drugs.

次要结局

未报告次要终点

研究者

发起方
Medtronic Cardiac Rhythm and Heart Failure
申办方类型
Industry
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验

已完成
不适用
Study to clinically evaluate the QT/QTc interval prolongation potential of vericiguat in patients with stable coronary artery disease in a 2-arm, placebo-controlled, randomized, double-blind, double-dummy design including a vericiguat multiple-dose part with fixed up-titration periods and moxifloxacin as positive control (for assay sensitivity testing, nested into the placebo treatment)cardiovascular disease
NL-OMON46553Bayer30
已完成
1 期
Study to Evaluate the QT / QTc Interval Prolongation Potential of VericiguatCoronary Artery Disease
NCT03504982Bayer74
已完成
1 期
A Study of QT and QTc Intervals in Patients Administered Extended Release Paliperidone or QuetiapineSchizophreniaSchizoaffective Disorder
NCT00791622Johnson & Johnson Pharmaceutical Research & Development, L.L.C.110
尚未招募
不适用
Observational study of corrected QT interval prolongation in psychiatric patients following haloperidol injectioQTc prolongation after receiving intravenous or intramuscular haloperidol injection for the management of acute agitation in hospitalized psychiatric patientsintravenous haloperidolintramuscular haloperidolQTc prolongationcardiotoxicityelectrocardiographypsychiatric patientsantipsychoticsantipsychotic medicationacute agitationaggression
TCTR20240417001Research Unit Buddhachinaraj Phitsanulok Hospital110
已完成
1 期
Main Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained PatientsOpioid DependenceMethadone Withdrawal Syndrome
NCT01650649USWM, LLC (dba US WorldMeds)27